EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2
EGFR G719A	Non Small Cell Lung Cancer	EGFR G719A	Non Small Cell Lung Cancer	dacomitinib Sensitive: C2 – Inclusion Criteria dacomitinib Sensitive : C2	dacomitinib Sensitive: C2 – Inclusion Criteria dacomitinib Sensitive : C2
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	Z650 Sensitive: C2 – Inclusion Criteria Z650 Sensitive : C2	Z650 Sensitive: C2 – Inclusion Criteria Z650 Sensitive : C2
HER-2 Y772_A775dup	Non Small Cell Lung Cancer	HER-2 Y772_A775dup	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 G778_P780dup	Non Small Cell Lung Cancer	HER-2 G778_P780dup	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 A775_G776insYVMA	Non Small Cell Lung Cancer	HER-2 A775_G776insYVMA	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 M774delinsWLV	Non Small Cell Lung Cancer	HER-2 M774delinsWLV	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 P780-Y781insGSP	Non Small Cell Lung Cancer	HER-2 P780-Y781insGSP	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 amplification	Non Small Cell Lung Cancer	HER-2 amplification	Non Small Cell Lung Cancer	dacomitinib Resistant: C3 – Early Trials dacomitinib Resistant : C3	dacomitinib Resistant: C3 – Early Trials dacomitinib Resistant : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
EGFR amplification	Esophageal Squamous Cell Carcinoma	EGFR amplification	Esophageal Squamous Cell Carcinoma	Z650 Sensitive: C3 – Early Trials Z650 Sensitive : C3	Z650 Sensitive: C3 – Early Trials Z650 Sensitive : C3
EGFR exon 18 mutation	Non Small Cell Lung Cancer	EGFR exon 18 mutation	Non Small Cell Lung Cancer	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3
EGFR exon 19 deletion + EGFR G724S	Non Small Cell Lung Cancer	EGFR exon 19 deletion + EGFR G724S	Non Small Cell Lung Cancer	dacomitinib Resistant: C3 – Early Trials dacomitinib Resistant : C3	dacomitinib Resistant: C3 – Early Trials dacomitinib Resistant : C3
EGFR exon 19 deletion + EGFR K754E	Non Small Cell Lung Cancer	EGFR exon 19 deletion + EGFR K754E	Non Small Cell Lung Cancer	dacomitinib Resistant: C3 – Early Trials dacomitinib Resistant : C3	dacomitinib Resistant: C3 – Early Trials dacomitinib Resistant : C3
EGFR L858R + EGFR E709X	Non Small Cell Lung Cancer	EGFR L858R + EGFR E709X	Non Small Cell Lung Cancer	dacomitinib Resistant: C3 – Early Trials dacomitinib Resistant : C3	dacomitinib Resistant: C3 – Early Trials dacomitinib Resistant : C3
EGFR D770 delinsGY	Non Small Cell Lung Cancer	EGFR D770 delinsGY	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
EGFR exon 18 deletion	Non Small Cell Lung Cancer	EGFR exon 18 deletion	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
EGFR L747P	Non Small Cell Lung Cancer	EGFR L747P	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
EGFR exon 21 mutation + EGFR L858R	Non Small Cell Lung Cancer	EGFR exon 21 mutation + EGFR L858R	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
EGFR G719A + EGFR I706T	Non Small Cell Lung Cancer	EGFR G719A + EGFR I706T	Non Small Cell Lung Cancer	dacomitinib Sensitive: C4 – Case Studies dacomitinib Sensitive : C4	dacomitinib Sensitive: C4 – Case Studies dacomitinib Sensitive : C4
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	dacomitinib Sensitive: C4 – Case Studies dacomitinib Sensitive : C4	dacomitinib Sensitive: C4 – Case Studies dacomitinib Sensitive : C4
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	bevacizumab + dacomitinib Sensitive: C4 – Case Studies bevacizumab + dacomitinib Sensitive : C4	bevacizumab + dacomitinib Sensitive: C4 – Case Studies bevacizumab + dacomitinib Sensitive : C4

pan-HER inhibitor

pan-HER inhibitor

Associations(41)

Associations
(41)